Webb20 maj 2015 · Platinum rechallenge chemotherapy is a treatment option and its efficacy was reported a few previous studies. However, there is a heterogeneity in sensitive relapsed SCLC, and some patients showed high sensitivity with an extremely long-term TFI. The role of platinum rechallenge in these highly sensitive SCLC patients is unknown. Webb29 okt. 2024 · Rechallenge is still a valuable option against regorafenib in patients who achieved disease control in one of the first two lines of therapy in patients with mCRC. …
Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non …
Webbbe considered for drug rechallenge. Increasingly, drug rechallenge has been incorporated into controlled clini-cal trials of critical therapeutics. Recent prospective clinical studies examining hundreds of rechallenge events currently define a positive drug rechallenge as an ALT level of 3-53 ULN or greater, which general- Webb29 okt. 2024 · Rechallenge of previous lines of well-tolerated systemic chemotherapy regimens with previously administered therapies may be a valuable therapeutic strategy in patients with heavily-treated mCRC. 4 PDF Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. D. … by366
Rechallenge with clozapine following leucopenia or neutropenia …
Webb6 feb. 2013 · Challenge – In our pharmacovigilance world, this refers to the giving of the drug to the patient during the AE or treatment in question. That is, a patient is started … WebbConclusion: Clozapine rechallenge is a reasonable clinical option after return to baseline for patients who had developed neutropenia and neuroleptic malignant syndrome, but not after agranulocytosis or myocarditis. Data are insufficient to formulate rechallenge guidelines for any other clozapine-related adverse effects. Webb2 apr. 2024 · Among patients with relapsed small-cell lung cancer (SCLC), those who relapse > 90 days after first-line chemotherapy are classified sensitive relapse. … cfo-as-a-service